CN110339205B - 富氢水组合物在抑制六价铬诱导的df-1细胞内质网应激及自噬中的应用 - Google Patents
富氢水组合物在抑制六价铬诱导的df-1细胞内质网应激及自噬中的应用 Download PDFInfo
- Publication number
- CN110339205B CN110339205B CN201910763868.XA CN201910763868A CN110339205B CN 110339205 B CN110339205 B CN 110339205B CN 201910763868 A CN201910763868 A CN 201910763868A CN 110339205 B CN110339205 B CN 110339205B
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- autophagy
- endoplasmic reticulum
- rich
- rich water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229910052739 hydrogen Inorganic materials 0.000 title claims abstract description 101
- 239000001257 hydrogen Substances 0.000 title claims abstract description 101
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims abstract description 99
- 230000004900 autophagic degradation Effects 0.000 title claims abstract description 50
- 210000002472 endoplasmic reticulum Anatomy 0.000 title claims abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000002401 inhibitory effect Effects 0.000 title abstract description 16
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 title abstract description 9
- 210000004027 cell Anatomy 0.000 claims abstract description 56
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims abstract description 43
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims abstract description 43
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920000057 Mannan Polymers 0.000 claims abstract description 10
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 10
- 239000000661 sodium alginate Substances 0.000 claims abstract description 10
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 10
- 239000007320 rich medium Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000011651 chromium Substances 0.000 abstract description 37
- 230000035882 stress Effects 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 10
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 10
- 101150112743 HSPA5 gene Proteins 0.000 description 10
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 10
- 101150028578 grp78 gene Proteins 0.000 description 10
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 description 9
- 102100037919 Insulin-like growth factor 2 mRNA-binding protein 2 Human genes 0.000 description 9
- 108091008010 PERKs Proteins 0.000 description 9
- 238000001262 western blot Methods 0.000 description 8
- 102000004072 Beclin-1 Human genes 0.000 description 7
- 108090000524 Beclin-1 Proteins 0.000 description 7
- 238000012258 culturing Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 210000004957 autophagosome Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000004445 quantitative analysis Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 4
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241001506137 Rapa Species 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108020005087 unfolded proteins Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005033 autophagosome formation Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 1
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710151717 Stress-related protein Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000002886 autophagic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009211 stress pathway Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 230000004906 unfolded protein response Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910763868.XA CN110339205B (zh) | 2019-08-19 | 2019-08-19 | 富氢水组合物在抑制六价铬诱导的df-1细胞内质网应激及自噬中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910763868.XA CN110339205B (zh) | 2019-08-19 | 2019-08-19 | 富氢水组合物在抑制六价铬诱导的df-1细胞内质网应激及自噬中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110339205A CN110339205A (zh) | 2019-10-18 |
CN110339205B true CN110339205B (zh) | 2021-08-24 |
Family
ID=68180762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910763868.XA Active CN110339205B (zh) | 2019-08-19 | 2019-08-19 | 富氢水组合物在抑制六价铬诱导的df-1细胞内质网应激及自噬中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110339205B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114984046B (zh) * | 2022-05-05 | 2023-07-18 | 山东鑫谷健康产业有限公司 | 富氢水组合物及其在缓解动物温度应激中的应用 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1556795A (zh) * | 2001-09-21 | 2004-12-22 | 霍夫曼-拉罗奇有限公司 | 3-脱氧-维生素d3类似物酯 |
CN101138647A (zh) * | 2006-09-08 | 2008-03-12 | 远东纺织股份有限公司 | 制备覆膜基材用的组成物及覆膜基材的制法及其制品 |
CN101528691A (zh) * | 2006-08-22 | 2009-09-09 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
CN102000109A (zh) * | 2010-09-30 | 2011-04-06 | 泰山医学院 | 基于氢为治疗物质的药物制剂及其制备方法 |
WO2014079911A3 (en) * | 2012-11-21 | 2015-04-02 | Tata Steel Ijmuiden B.V. | Method for electrodeposition of chromium containing coatings from trivalent chromium based electrolytes |
WO2017180587A2 (en) * | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
WO2018128167A1 (ja) * | 2017-01-06 | 2018-07-12 | 株式会社新菱 | 肌用シート |
WO2018131505A1 (ja) * | 2017-01-11 | 2018-07-19 | 株式会社新菱 | 水素ガス含有ゲル、ならびにこれを含む食品および化粧料 |
CN108779495A (zh) * | 2016-04-06 | 2018-11-09 | 雀巢产品技术援助有限公司 | 调节bckdh的方法 |
CN109070037A (zh) * | 2016-04-14 | 2018-12-21 | 株式会社新菱 | 含气基材及其制造方法 |
CN109292984A (zh) * | 2018-10-09 | 2019-02-01 | 浙江海洋大学 | 水产养殖用水质改良剂及其制备方法 |
CN109350618A (zh) * | 2018-12-10 | 2019-02-19 | 山东农业大学 | 自噬调节剂在消除牛乳腺上皮细胞内金黄色葡萄球菌中的应用 |
CN109674782A (zh) * | 2019-02-02 | 2019-04-26 | 山东农业大学 | 紫番茄花青素在调控铬诱导的lmh细胞自噬中的应用 |
WO2019109168A1 (en) * | 2017-12-07 | 2019-06-13 | Teck Resources Limited | Process for treatment of mine impacted water |
-
2019
- 2019-08-19 CN CN201910763868.XA patent/CN110339205B/zh active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1556795A (zh) * | 2001-09-21 | 2004-12-22 | 霍夫曼-拉罗奇有限公司 | 3-脱氧-维生素d3类似物酯 |
CN101528691A (zh) * | 2006-08-22 | 2009-09-09 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
CN101138647A (zh) * | 2006-09-08 | 2008-03-12 | 远东纺织股份有限公司 | 制备覆膜基材用的组成物及覆膜基材的制法及其制品 |
CN102000109A (zh) * | 2010-09-30 | 2011-04-06 | 泰山医学院 | 基于氢为治疗物质的药物制剂及其制备方法 |
WO2014079911A3 (en) * | 2012-11-21 | 2015-04-02 | Tata Steel Ijmuiden B.V. | Method for electrodeposition of chromium containing coatings from trivalent chromium based electrolytes |
CN108779495A (zh) * | 2016-04-06 | 2018-11-09 | 雀巢产品技术援助有限公司 | 调节bckdh的方法 |
WO2017180587A2 (en) * | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
CN109070037A (zh) * | 2016-04-14 | 2018-12-21 | 株式会社新菱 | 含气基材及其制造方法 |
WO2018128167A1 (ja) * | 2017-01-06 | 2018-07-12 | 株式会社新菱 | 肌用シート |
WO2018131505A1 (ja) * | 2017-01-11 | 2018-07-19 | 株式会社新菱 | 水素ガス含有ゲル、ならびにこれを含む食品および化粧料 |
WO2019109168A1 (en) * | 2017-12-07 | 2019-06-13 | Teck Resources Limited | Process for treatment of mine impacted water |
CN109292984A (zh) * | 2018-10-09 | 2019-02-01 | 浙江海洋大学 | 水产养殖用水质改良剂及其制备方法 |
CN109350618A (zh) * | 2018-12-10 | 2019-02-19 | 山东农业大学 | 自噬调节剂在消除牛乳腺上皮细胞内金黄色葡萄球菌中的应用 |
CN109674782A (zh) * | 2019-02-02 | 2019-04-26 | 山东农业大学 | 紫番茄花青素在调控铬诱导的lmh细胞自噬中的应用 |
Non-Patent Citations (2)
Title |
---|
The regulatory role of COX-2 in the interaction between Cr(VI)-induced endoplasmic reticulum stress and autophagy in DF-1 cells;Peng Chen et al.;《Ecotoxicology and Environmental Safety》;20181204;第170卷;第112-119页 * |
环氧合酶2(COX-2)对Cr(VI)致DF-1内质网自噬的调控研究;陈鹏;《万方·学位论文》;20181101;第35-37页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110339205A (zh) | 2019-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shang et al. | Resveratrol protects the myocardium in sepsis by activating the phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and inhibiting the nuclear factor-κB (NF-κB) signaling pathway | |
Ni et al. | The critical role of proteolytic relay through cathepsins B and E in the phenotypic change of microglia/macrophage | |
Cowley Jr et al. | Evidence of the importance of Nox4 in production of hypertension in Dahl salt-sensitive rats | |
Hou et al. | Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy | |
Dong et al. | Juglanin suppresses fibrosis and inflammation response caused by LPS in acute lung injury | |
You et al. | Macrophages directly mediate diabetic renal injury | |
Li et al. | l-Theanine prevents alcoholic liver injury through enhancing the antioxidant capability of hepatocytes | |
Nunes et al. | Intestinal anti-inflammatory activity of red wine extract: Unveiling the mechanisms in colonic epithelial cells | |
Wang et al. | Icariin prevents extracellular matrix accumulation and ameliorates experimental diabetic kidney disease by inhibiting oxidative stress via GPER mediated p62-dependent Keap1 degradation and Nrf2 activation | |
Wang et al. | Alleviation of acute lung injury in rats with sepsis by resveratrol via the phosphatidylinositol 3-kinase/nuclear factor-erythroid 2 related factor 2/heme oxygenase-1 (PI3K/Nrf2/HO-1) pathway | |
Bai et al. | Eriodictyol inhibits high glucose‐induced extracellular matrix accumulation, oxidative stress, and inflammation in human glomerular mesangial cells | |
Zou et al. | Endoplasmic reticulum stress‐mediated autophagy protects against lipopolysaccharide‐induced apoptosis in HL‐1 cardiomyocytes | |
Hwang et al. | Brazilin and Caesalpinia sappan L. extract protect epidermal keratinocytes from oxidative stress by inducing the expression of GPX7 | |
Chen et al. | Hydrogen alleviates cell damage and acute lung injury in sepsis via PINK1/Parkin-mediated mitophagy | |
Chen et al. | Mesenchymal Stem Cells Attenuate Diabetic Lung Fibrosis via Adjusting Sirt3‐Mediated Stress Responses in Rats | |
Liu et al. | Phlorizin exerts potent effects against aging induced by D-galactose in mice and PC12 cells | |
Wohua et al. | Glutaredoxin 2 (GRX2) deficiency exacerbates high fat diet (HFD)-induced insulin resistance, inflammation and mitochondrial dysfunction in brain injury: A mechanism involving GSK-3β | |
Oyarzabal et al. | Mitochondrial response to the BCKDK-deficiency: some clues to understand the positive dietary response in this form of autism | |
Ramez et al. | High‐intensity interval training increases myocardial levels of Klotho and protects the heart against ischaemia–reperfusion injury | |
Ying et al. | Zeaxanthin ameliorates high glucose-induced mesangial cell apoptosis through inhibiting oxidative stress via activating AKT signalling-pathway | |
Qin et al. | Sirtuin 6 mitigated LPS‐induced human umbilical vein endothelial cells inflammatory responses through modulating nuclear factor erythroid 2‐related factor 2 | |
Habib et al. | Tuberin inhibits production of the matrix protein fibronectin in diabetes | |
Salami et al. | Therapeutic potential of resveratrol in diabetic nephropathy according to molecular signaling | |
CN110339205B (zh) | 富氢水组合物在抑制六价铬诱导的df-1细胞内质网应激及自噬中的应用 | |
Mi et al. | Mitofusin 2 attenuates the histone acetylation at collagen IV promoter in diabetic nephropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191018 Assignee: Shandong Xingu Health Industry Co.,Ltd. Assignor: SHANDONG DEXIN BIOTECHNOLOGY CO.,LTD. Contract record no.: X2022980016656 Denomination of invention: Application of hydrogen rich water composition in inhibiting endoplasmic reticulum stress and autophagy of DF-1 cells induced by hexavalent chromium Granted publication date: 20210824 License type: Common License Record date: 20220927 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of hydrogen rich water combination in inhibiting hexavalent chromium induced endoplasmic reticulum stress and autophagy in DF-1 cells Effective date of registration: 20231129 Granted publication date: 20210824 Pledgee: Shandong Huimin Rural Commercial Bank Co.,Ltd. Pledgor: SHANDONG DEXIN BIOTECHNOLOGY CO.,LTD. Registration number: Y2023980068263 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |